Trial Profile
EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2020
Price :
$35
*
At a glance
- Drugs Nicotinamide-riboside/pterostilbene (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Elysium Health
- 06 Apr 2018 New trial record
- 29 Mar 2018 According to the Elysium Health media release, company plans to initiate this trial by the fourth quarter of 2018 in collaboration with Mayo Clinic.